American Association for Cancer Research
Browse

FIGURE 2 from A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer

Download (796.89 kB)
figure
posted on 2023-06-05, 14:20 authored by Esteban Terzo, Shruti A. Apte, Simran Padhye, Saleh Rashed, Wesley Austin, Michael Caponegro, Anupama Reddy, Shuhao Shi, Christy Wang, Roger B. Clark, David Sidransky, Vijay Modur, Vasudeo Badarinarayana

ZKN-157 selectively inhibits new protein synthesis in a sensitive colorectal cancer cell line. A, Volcano plot showing heavy-isotope intensities (newly synthesized protein abundance) for 2867 proteins detected at 24-hour timepoint. Protein were classified as follows: Decreased (log2FC < −0.4, Padjusted < 0.05, red), Downward Trend (log2FC < −0.4, Padjusted > 0.05, pink), Increased (log2FC > 0.4, Padjusted < 0.05, dark green), Upward Trend (log2FC > 0.4, Padjusted > 0.05, light green), Unchanged (−0.4 < log2FC < 0.4, Padjusted > 0.05, dark gray). Dotted lines indicate −0.5 and 0.5 log2FC values. B, Bar graph plotting percent protein fraction of heavy-isotope intensity (categorized as in A) at 24-hour timepoint versus positively charged regions. Positive charge windows were generated by assigning K and R residues a positive 1 charge and all other amino acid residues a charge of 0. Average charge values were then calculated along a 10-amino acid long sliding window for each protein's amino acid sequence (starting at the first residue and ending at the last complete set of 10 residues). C, Overrepresentation analysis and pathway enrichment in significantly downregulated proteins from A are shown. Count refers to the number of genes found in each pathway while gene ratio refers to the count divided by all genes in the pathway. D, Bar graph showing nascent protein abundance for 68 Ribosomal proteins from heavy-isotope intensity analysis at 24-hour timepoint (categorized as in A). The dotted line indicates −0.4 log2FC value.

Funding

n/a

History

ARTICLE ABSTRACT

This study demonstrates that ribosome heterogeneity in cancer can be exploited to develop selective ribogenesis inhibitors. The colorectal cancer CMS2 subtype, with a high unmet need for therapeutics, shows vulnerability to our novel selective ribosome modulator. The mechanism suggests that other cancer subtypes with high MYC activation could also be targeted.

Usage metrics

    Cancer Research Communications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC